Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects
NCT ID: NCT00043966
Last Updated: 2006-07-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
200 participants
INTERVENTIONAL
2002-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lopinavir/ritonavir
Tenofovir DF
Emtricitabine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* If female, subject is not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing potential and practicing one of the following methods of birth control: \*condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD) \*contraceptives (oral or parenteral) for three months prior to study drug administration) \*a vasectomized partner \*total abstinence from sexual intercourse
* If female, the results of a urine pregnancy test performed at screening (urine specimen obtained no earlier than 28 days prior to study drug administration) and a urine pregnancy test performed on Study Day -1 are both negative and the subject agrees to use a barrier method of contraception throughout the study.
* Subject is not breast-feeding.
* Vital signs, physical examination and laboratory results do not exhibit evidence of acute illness.
* Subject has no significant history of cardiac, renal, neurologic, psychiatric, oncologic, endocrinologic, metabolic or hepatic disease that would adversely affect his/her participating in this study.
* Subject does not require and agrees not to take any of the following medications for the duration of the study: midazolam, triazolam, terfenadine, astemizole, cisapride, pimozide, propafenone, flecainide, certain ergot derivatives (ergotamine, dihydroergotamine, ergonovine, and methylergonovine), rifampin, lovastatin, simvastatin, and St. John's wort.
* Subject agrees not to take any medication during the study, including over-the-counter medicine, herbal medications, alcohol or recreational drugs without the knowledge and permission of the principal investigator.
* Subject has a Karnofsky Score greater than or equal to 70
* Subject has not been treated for an active AIDS-defining opportunistic infection within 30 days of screening. Subjects who are on stable maintenance therapy for an opportunistic infection may be enrolled after consultation with Abbott.
* Subject is naive to antiretroviral treatment (\< 7 days ARV treatment).
* Subject has a plasma HIV RNA level of greater than 1,000 copies/mL at screening.
* Subject agrees to take all doses of the lopinavir/ritonavir from the bottles provided by the sponsor (rather than take doses from a personal "dosette" box).
* Subject has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), after the nature of the study has been explained and the subject has had the opportunity to ask questions. The informed consent must be signed before any study-specific procedures are performed.
Exclusion Criteria
* Subject has a recent (within the past 6 months) history of drug and/or alcohol abuse.
* Subject has a positive result on the screening tests for drugs of abuse.
* Subject has a history of substance abuse or psychiatric illness that could preclude adherence with the protocol.
* Screening laboratory analyses show any of the following abnormal laboratory results: \*Hemoglobin ≤ 8.0 g/dL \*Absolute neutrophil count ≤ 750 cells/µL \*Platelet count ≤ 50,000 per mL \*ALT or AST ≥ 3.0 x Upper Limit of Normal (ULN) \*Creatinine ≥ 1.5 x Upper Limit of Normal (ULN)
* Subject has received any investigational drug within 30 days prior to study drug administration.
* For any reason, subject is considered by the investigator to be an unsuitable candidate for the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abbott
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Scott Brun, M.D.
Role: STUDY_DIRECTOR
Global Project Head, Antiviral Global Project Team
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Phoenix Body Positive
Phoenix, Arizona, United States
Pacific Oaks Research
Beverly Hills, California, United States
Orange County Center for Special Immunology
Fountain Valley, California, United States
Living Hope Clinical Foundation
Long Beach, California, United States
AIDS Healthcare Foundation Research Center
Los Angeles, California, United States
IDS Research Initiative
Altamonte Springs, Florida, United States
South Florida Clinical Research
Atlantis, Florida, United States
Comprehensive Care Center
Fort Lauderdale, Florida, United States
Gary J. Richmond, MD
Fort Lauderdale, Florida, United States
Associates in Research
Fort Myers, Florida, United States
Morris, Sklaver, Mestre & Denney, M.D., PA
Plantation, Florida, United States
Health Positive
Safety Harbor, Florida, United States
Infectious Disease Research Institute, Inc.
Tampa, Florida, United States
Treasure Coast Infectious Disease Consultants
Vero Beach, Florida, United States
AIDS Research Consortium of Atlanta Inc.
Atlanta, Georgia, United States
Donna E. Sweet, MD
Wichita, Kansas, United States
Drs. Combs and Lutz
New Orleans, Louisiana, United States
St. Michael's Medical Center
Newark, New Jersey, United States
Polari Medical Group
New York, New York, United States
Wake Forest University School of Medicine
Winston-Salem, North Carolina, United States
Akron Infectious Disease, Inc.
Akron, Ohio, United States
Associates in Medical and Mental Health, P.C.
Tulsa, Oklahoma, United States
The Research & Education Group
Portland, Oregon, United States
Philadelphia FIGHT
Philadelphia, Pennsylvania, United States
Triangle Medical
Philadelphia, Pennsylvania, United States
Central Texas Clinical Research
Austin, Texas, United States
Joseph C. Gathe, Jr, MD
Houston, Texas, United States
Southampton Medical Group
Houston, Texas, United States
Hampton Roads Medical Specialists
Hampton, Virginia, United States
Ground Zero Medical Centre / AIDS Research Initiative
Darlinghurst, New South Wales, Australia
Holdsworth House General Practice
Darlinghurst, New South Wales, Australia
Hopital Saint Louis
Paris, Cedex 10, France
Hopital Saint Antoine
Paris, Cedex 12, France
Hopital Tenon
Paris, Cedex 20, France
CHU Kremlin Bicetre
Le Kremlin-Bicêtre, , France
Hopital l'Archet
Nice, , France
Hopital Bichat
Paris, , France
Klinik I fur Innere Medizin der Universitat zu Koln
Cologne, , Germany
Klinikum J.W. Goethe Universitat
Frankfurt, , Germany
Tan Tock Seng Hospital
Tan Tock Seng, , Singapore
Hospital Germans Trias I Pujol
Badalona, , Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, , Spain
Hospital Vall D'Hebron
Barcelona, , Spain
L'Hospitalet de Llobregat
Barcelona, , Spain
Hospital 12 de Octubre
Madrid, , Spain
Hospital La Paz
Madrid, , Spain
Hospital de Mostolesi
Madrid, , Spain
Brighton General Hospital
E. Sussex, , United Kingdom
Royal Free Hospital
London, , United Kingdom
The Caldecot Centre King's Healthcare NHS Trust
London, , United Kingdom
St. Stephen's Centre Chelsea & Westminster Hospital
London, , United Kingdom
St. Mary Hospital
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. J Infect Dis. 2007 Dec 15;196(12):1773-8. doi: 10.1086/523704.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M02-418
Identifier Type: -
Identifier Source: org_study_id